ProQR Therapeutics N.V. Stock News

Analysts are notably more bearish on the company following unhappy news about its leading drug candidate.

Analysts are notably more bearish on the company following unhappy news about its leading drug candidate.

ProQR (PRQR) lead candidate sepofarsen did not meet primary and secondary goals in phase II/III study.

Citi has downgraded ProQR Therapeutics <> to Neutral from Buy after the clinical-stage biotech company reported that its pivotal Phase 2/3 study for RNA therapy sepofarsen did

Analysts are notably more bearish on the company following unhappy news about its leading drug candidate.

ProQR (PRQR) lead candidate sepofarsen did not meet primary and secondary goals in phase II/III study.

Analysts have provided the following ratings for ProQR Therapeutics (NASDAQ:PRQR) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 1 0 0

Analysts have provided the following ratings for ProQR Therapeutics (NASDAQ: PRQR ) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 1 0 0 0 Last 30D 2 1 0 0 0 1M Ago 1 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 0 0 0 0 0 In the last 3 months, 4 analysts have offered 12-month price targets for ProQR Therapeutics. The company has an average price target of $9.75 with a high of $19.00 and a low of $4.00. Below is a summary of how these 4 analysts rated ProQR Therapeutics over the past 3 months. The greater the number Full story available on Benzinga.com

Upgrades According to Mizuho, the prior rating for Murphy Oil Corp (NYSE:MUR) was changed from Neutral to Buy. In the fourth quarter, Murphy Oil showed an EPS of $0.40, compared to $0.09 from the yea

On Friday, 106 companies reached new 52-week lows. Things to Consider About Today''s 52-Week Lows: Air Products & Chemicals (NYSE: APD ) is the largest company in terms of market cap to set a new 52-week low this morning. Enveric Biosciences (NASDAQ: ENVB ) was the smallest firm on a market cap basis to set a new 52-week low. ProQR Therapeutics (NASDAQ: PRQR ) was the biggest loser of the morning session, as it dropped 74.33% to reach its new 52-week low. Skillsoft (NYSE: SKIL ) saw the sharpest rebound, as shares ascended 0.0%, reversing after hiting a new 52-week low. Here is a list of stocks that set new 52-week lows on Friday: Air Products & Chemicals (NYSE: APD ) shares set a new yearly low of $249.22 this morning. The stock was down 1.16% on the session. Lumen Technologies (NYSE: LUMN ) shares set a new 52-week low of $10.46. The stock traded down 2.91%. Black Knight (NYSE: BKI ) stock broke to a new 52-week low of $67.94 on Friday. Shares of the company traded down 0.97%. IAA (NYSE: IAA ) shares were down 16.85% for the day, having made a 52-week low of $36.78.

Sepofarsen's failure to meet efficacy endpoints in the Illuminate trial isn't sitting well with investors.

Sepofarsen''s failure to meet efficacy endpoints in the Illuminate trial isn''t sitting well with investors.

NEW YORK , Feb. 11, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SENS, PRQR, SRGA, ASTR, and UAA. … Full story available on Benzinga.com

Gainers: Orphazyme ORPH +22%. Y-mAbs Therapeutics YMAB +11%. Oscar Health (OSCR) +9%. Theravance Biopharma TBPH +9%. VistaGen Therapeutics (VTGN) +8%.Losers: ProQR Therapeutics PRQR -72%

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adcom Rules That Lilly May Have To Conduct Additional Studies For Co-Developed Oncology Drug Eli Lilly